News
MYCOF
0.011
NaN%
--
Weekly Report: what happened at MYCOF last week (0415-0419)?
Weekly Report · 2d ago
Weekly Report: what happened at MYCOF last week (0408-0412)?
Weekly Report · 04/15 09:56
Weekly Report: what happened at MYCOF last week (0401-0405)?
Weekly Report · 04/08 09:59
Weekly Report: what happened at MYCOF last week (0325-0329)?
Weekly Report · 04/01 09:58
Weekly Report: what happened at MYCOF last week (0318-0322)?
Weekly Report · 03/25 09:59
Weekly Report: what happened at MYCOF last week (0311-0315)?
Weekly Report · 03/18 09:58
Weekly Report: what happened at MYCOF last week (0304-0308)?
Weekly Report · 03/11 09:57
Weekly Report: what happened at MYCOF last week (0226-0301)?
Weekly Report · 03/04 09:58
Oregon House passes bill to end hard drug decriminalization
New Zealand this week reversed a ban on tobacco sales to younger generations. Thailand just announced that it would ban the use of recreational cannabis by the end of this year. Oregon is getting second thoughts on decriminalizing hard drugs. The first U.S. State to decriminalize hard drugs has declared a fentanyl state of emergency.
Seeking Alpha · 03/01 11:42
Weekly Report: what happened at MYCOF last week (0219-0223)?
Weekly Report · 02/26 10:04
Weekly Report: what happened at MYCOF last week (0212-0216)?
Weekly Report · 02/19 10:05
Psychedelics Headlines: Trauma-Informed Care, Valentine's Day & MDMA, Academics On Drugs And More
Benzinga's psychedelics headlines roundup includes a look at the last few days of January and the first two weeks of February 2024. A review of Indigenous psilocybin mushroom practices: An annotated bibliography. Psychedelics center developed a new rating scale for the effects of MDMA, ketamine and other drugs.
Benzinga · 02/15 15:55
Psychedelic stocks gain after FDA priority review for MDMA therapy
Psychedelic stocks gain after FDA priority review for MDMA therapy. If approved, MDMA could become the first psychedelic-assisted therapy. The new drug application seeks approval of MDMA for post-traumatic stress disorder. The FDA has set a target action date of August 11, 2024 for its review.
Seeking Alpha · 02/12 17:13
Weekly Report: what happened at MYCOF last week (0205-0209)?
Weekly Report · 02/12 10:00
Weekly Report: what happened at MYCOF last week (0129-0202)?
Weekly Report · 02/05 10:04
Weekly Report: what happened at MYCOF last week (0122-0126)?
Weekly Report · 01/29 09:59
Weekly Report: what happened at MYCOF last week (0115-0119)?
Weekly Report · 01/22 10:01
Weekly Report: what happened at MYCOF last week (0108-0112)?
Weekly Report · 01/15 09:59
Weekly Report: what happened at MYCOF last week (0101-0105)?
Weekly Report · 01/08 10:01
Weekly Report: what happened at MYCOF last week (1225-1229)?
Weekly Report · 01/01 09:59
More
Webull provides a variety of real-time MYCOF stock news. You can receive the latest news about Mydecine Innovations Group Inc through multiple platforms. This information may help you make smarter investment decisions.
About MYCOF
Mydecine Innovations Group Inc. is a Canada-based biopharma and life sciences company. The Company is focused on the research, development and acceptance of alternative nature-sourced medicine. Its portfolio of companies includes Mydecine Health Sciences (MHS), Mindleap Health Inc. (Mindleap) and NeuroPharm, Inc (NPI). MHS is focused on developing fungtional mushroom products and psychedelic medicines for the consumer and professional healthcare market. NPI is a veterans-focused healthcare company that is developing pharmaceutical and natural health products for mental wellness in vulnerable populations, including veterans, emergency medical services (EMS) personnel and other high-risk constituencies. NPI is developing psilocybin-assisted psychotherapy to treat chronic post-traumatic stress disorder (PTSD). Mindleap offers a digital health platform that enables people connect with mental health specialists, who can help them to develop habits for a healthy mind.